. Author manuscript; available in PMC: 2021 Nov 1.

Published in final edited form as: Liver Transpl. 2020 Aug 19;26(11):1430–1440. doi: 10.1002/lt.25837

Table 1:

Immunosuppressive Therapy per Study Group

Time Post LT^* (post-operative day (POD))	Budesonide Group N=20	Control Group N=20
POD 0–3	SIS^ǂ + Intravenous corticosteroids	SIS^ǂ + Intravenous corticosteroids
POD 4–30	SIS^ǂ + Budesonide 9 mg	SIS^ǂ + Prednisone 60 mg tapered to 15 mg
POD 31–45	SIS^ǂ + Budesonide 6 mg	SIS^ǂ + Prednisone 10 mg
POD 46–90	SIS^ǂ + Budesonide 3 mg	SIS^ǂ + Prednisone 10 mg tapered to discontinue
POD ≥ 91	SIS^ǂ,¥	SIS^ǂ,¥

LT: Liver Transplant

^ǂ

SIS: standard immune suppression which consisted of the following: tacrolimus twice daily dosed to achieve goal trough level 8–12 ng/ml + mycophenolate mofetil 500 mg twice daily, +/− Thymoglobulin with goal CD3 suppression < 25 with delayed initiation of tacrolimus

^¥

If autoimmune hepatitis prior to LT continue prednisone 5 mg daily indefinitely